Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2007

View Archived Issues

Discovery receives FDA guidance on path to Surfaxin approval

Progress in phase II trial of AL-208 for MCI in CABG

CLS-001 begins phase II study in rosacea

Fast track designation for SQ-109 for treatment of pulmonary TB

IND accepted for iCo-007 in diabetic macular edema

FDA accepts sNDA for Doxil + Velcade in relapsed/refractory multiple myeloma

Geron licenses MaxCyte technology for use in cancer vaccines

CollaRx gentamicin cleared to begin phase II study for infected diabetic foot ulcers

Anticancer drug WBI-2100 stimulates immune system in preclinical studies

Shire licenses North American rights to SPD-754 to Avexa

RhuDex studied for rheumatoid arthritis in new phase IIa study

NDA resubmission for indiplon capsules planned for Q2 2007

Samaritan inlicenses rights to Infasurf

Enrollment begins in phase III ophthalmic trials of difluprednate

Analysis bolsters SAINT I findings of NXY-059 in ischemic stroke

Enzyme replacement therapy to be evaluated in metachromatic leukodystrophy/News in context

rHuPH20 increases bioavailability of large protein molecule therapeutic

Novel agents for thrombotic disorders disclosed in recent Pfizer and Bristol-Myers Squibb patents

Recent AstraZeneca patent imparts novel anxiolytic agents

E.U. approval for Lucentis in wet AMD

Pharmion files MAA for Thalidomide Pharmion for multiple myeloma

Recent patents announce novel antidiabetic agents

Pfizer recaps highlights of 2006

DCA inhibits cancer growth by normalizing mitochondrial function and promoting apoptosis

Medicure reviews Q2 highlights